Today's Weak On High Volume Stock: Retrophin (RTRX)
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Retrophin as such a stock due to the following factors:
- RTRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $11.6 million.
- RTRX has traded 592,555 shares today.
- RTRX is trading at 27.55 times the normal volume for the stock at this time of day.
- RTRX is trading at a new low 17.05% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RTRX with the Ticky from Trade-Ideas. See the FREE profile for RTRX NOW at Trade-Ideas
More details on RTRX:
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Currently there is 1 analyst that rates Retrophin a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Retrophin has been 648,900 shares per day over the past 30 days. Retrophin has a market cap of $750.7 million and is part of the health care sector and drugs industry. The stock has a beta of 0.82 and a short float of 14.7% with 7.91 days to cover. Shares are up 78.3% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Retrophin as a
. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 316.2% when compared to the same quarter one year ago, falling from $11.81 million to -$25.53 million.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, RETROPHIN INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The current debt-to-equity ratio, 0.56, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.84 is somewhat weak and could be cause for future problems.
- RETROPHIN INC has improved earnings per share by 5.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, RETROPHIN INC reported poor results of -$6.02 versus -$2.38 in the prior year. This year, the market expects an improvement in earnings ($0.76 versus -$6.02).
- Investors have driven up the company's shares by 100.84% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the future course of this stock, we feel that the risks involved in investing in RTRX do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full Retrophin Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.